Showing results (921-930 of 3,473) with videos related to

Sort By:
Pageof 348
Clinical Pharmacokinetics|June 29, 2006
Modelling the anti-migraine effects of BIBN 4096 BS: a new calcitonin gene-related peptide receptor antagonistIñaki F Trocóniz, Jan-Markus Wolters, Christiane Tillmann, et al.
Clinical Pharmacokinetics|August 4, 2006
Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokineticsMona Darwish, Mary Kirby, Philmore Robertson, et al.
Clinical Pharmacokinetics|January 27, 2007
Efavirenz and nevirapine in HIV-1 infection : is there a role for clinical pharmacokinetic monitoring?Karen Dahri, Mary H H Ensom
Clinical Pharmacokinetics|May 24, 2007
A systematic review of limited sampling strategies for platinum agents used in cancer chemotherapyGabriel W Loh, Lillian S L Ting, Mary H H Ensom
Clinical Pharmacokinetics|May 24, 2007
Pharmacokinetics of taurolidine following repeated intravenous infusions measured by HPLC-ESI-MS/MS of the derivatives taurultame and taurinamide in glioblastoma patientsRuediger Stendel, Louis Scheurer, Kathrin Schlatterer, et al.
Clinical Pharmacokinetics|May 1, 2007
Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical responseMassimo C Mauri, Lucia S Volonteri, Alessandro Colasanti, et al.
Clinical Pharmacokinetics|October 20, 2006
Sirolimus population pharmacokinetic/pharmacogenetic analysis and bayesian modelling in kidney transplant recipientsNassim Djebli, Annick Rousseau, Guillaume Hoizey, et al.
Clinical Pharmacokinetics|May 25, 2006
Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokineticsHelen C Swaisland, Mireille V Cantarini, Rainard Fuhr, et al.
Clinical Pharmacokinetics|November 1, 1991
Pharmacokinetic optimisation of histamine H1-receptor antagonist therapyF E Simons, K J Simons
Clinical Pharmacokinetics|May 28, 2020
Metabolism and Pharmacokinetic Drug-Drug Interaction Profile of Vericiguat, A Soluble Guanylate Cyclase Stimulator: Results From Preclinical and Phase I Healthy Volunteer StudiesMichael Boettcher, Michael Gerisch, Maximilian Lobmeyer, et al.
Pageof 348